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ackground to the debate: Schizophrenia affects an 
estimated 25 million people in low- and middle-income 
countries, with an average lifetime risk of about 1%. The 
illness is associated with excess mortality from a variety 
of causes. A 2001 Institute of Medicine report on mental 
illness in developing countries found that in 1990, over 
two-thirds of people with schizophrenia in these countries 
were not receiving any treatment (http://www.nap.edu/
catalog/10111.html). The report found no evidence that the 
proportion of treated people in the developing world had 
increased since 1990. There is now a debate among mental 
health professionals in low-income countries over how best 
to improve patient care. In this article, three psychiatrists 
give their different viewpoints on the current status of 
treatment efforts for schizophrenia in the developing 
world and the measures that can be taken to increase the 
proportion of patients receiving treatment.
Vikram Patel’s Viewpoint: Non-Specialist 
Community Health Workers Should 
Play a Key Role in Delivering Care
Although schizophrenia is relatively rare, it is also arguably 
the most severe mental disorder. In many individuals, the 
disorder runs a chronic and relapsing course, leading to 
progressively worsening disability, loss of livelihoods and 
social networks, and increased risk of discrimination and 
human rights abuse. To consider what might be the best 
approach for treating schizophrenia in low- and middle-
income countries (LAMIC), we must ﬁ  rst address three 
questions: What is the burden of this disorder? What are the 
resources available for care? And what is the evidence base for 
the treatment of this disorder in LAMIC?
Assuming that the point prevalence of schizophrenia in 
LAMIC is the median ﬁ  gure reported in a recent systematic 
review—4.6 per 1,000 population [1]—and that the 
population of LAMIC is 5.3 billion [2], then about 25 million 
people with schizophrenia live in LAMIC. The health systems 
of LAMIC are woefully unprepared to address the myriad 
health and social needs of people with schizophrenia; in most 
parts of LAMIC, there is less than one qualiﬁ  ed mental health 
professional for half a million to a million people [3] (which 
will include about 2,500 to 5,000 people with schizophrenia). 
Therefore most people with schizophrenia in LAMIC 
probably receive little or no formal care.
What impact does this lack of care have on patients’ lives? 
A recent household study from Mozambique reported that up 
to half of the patients with psychotic disorders were reported 
by key informants in their households to be currently in poor 
health [4]. Traditional medicine was by far the most common 
type of health care accessed. Lack of services contributes to 
delayed treatment, which in turn leads to poorer long-term 
outcomes [5], higher direct and indirect costs of treatment 
with antipsychotic drugs [6], and increasing mortality [7–9].
Thus, the lack of evidence-based care, exacerbated by rapid 
changes in social and economic conditions in less developed 
countries that compromise the ability of informal systems to 
care for people with schizophrenia [9], represents a looming 
mental health crisis in these countries. Despite these scarce 
resources, there is now growing evidence that antipsychotic 
drugs and community-based, family-focused interventions are 
effective treatments in LAMIC [10]. The latter help reduce 
stigma, improve adherence to medication, and strengthen 
social integration.
How can these treatments be delivered in low-resource 
settings? The most appropriate model of care is a community-
based program that is affordable, feasible, acceptable, and 
evidence based. Who are the key health professionals needed 
to deliver such a model? Given the scarce specialist resources in 
LAMIC, the lion’s share of the service delivery would need to be 
the responsibility of non-specialist health workers. Indeed, the 
front line of the community mental health-care system need not 
even be represented by health workers at all, but may be made 
up of people who live in the community and are trained to 
provide a range of family- and community-based interventions.
Such care models are now being implemented by a number 
of community-based organizations such as Basic Needs (a 
mental health non-governmental organization operating in 
a number of developing countries and based in the United 
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Kingdom), and have been shown in quasi-experimental 
designs to be superior to simple outpatient care on clinical 
and functional outcomes [11]. These programs still require a 
health practitioner—who could be an appropriately trained 
physician or nurse practitioner—with sufﬁ  cient skills in 
diagnosis and drug treatment. The role of specialists may 
need to be carefully redeﬁ  ned; where available, outreach 
services provided by specialists in collaboration with local non-
governmental organizations are a clinically effective and cost-
effective approach that produces signiﬁ  cant improvements 
in functioning and decreased burden on the family [12]. In 
many places, however, the most feasible role for specialists 
might be to design programs, build capacity of non-specialist 
health workers, and supervise the quality of care delivered.
The ﬁ  rst step in a population-based model must be to 
improve awareness about the disorder and the service. The 
community mental health worker needs to establish close 
networks with members of grass-root, health service, and 
social welfare organizations. Next, the community mental 
health worker must identify probable cases of schizophrenia, 
preferably as early as possible after the onset of the disorder. 
The ideal model for case identiﬁ  cation is likely to be through 
the use of key informants (individuals who are familiar with 
the health status of members of the community they live in), 
a cost-effective method for identifying mental disorders in 
LAMIC [13]. Then the skilled health practitioner should 
make the diagnosis and initiate drug treatment. Health 
practitioners must also play close attention to the physical 
health needs of their patients, given that physical health 
problems are common in people with schizophrenia and are 
often neglected, contributing to higher mortality [14]. Health 
practitioners should also have access to an inpatient unit for 
the short-term care of patients who are acutely disturbed.
After this predominantly clinical phase, the focus of care 
shifts back to the community, involving three strategies: 
(1) Strengthening opportunities for paid employment; (2) 
building individual and family capacity to cope with the 
disorder (e.g., to support medication adherence); and (3) 
ensuring that the costs of long-term care are at least partly 
borne by an equitable ﬁ  nancing system, such as a voucher 
system, insurance plan, or ﬁ  xed monthly payments. The role 
of the community worker may extend to care for people 
with other severe neuropsychiatric disorders, such as mental 
retardation and epilepsy, which share many characteristics 
with schizophrenia (e.g., chronicity, disability, stigma, and 
loss of livelihood), and are also more likely to occur together. 
Community-based residential care will still be needed for the 
few individuals who are severely disabled and cannot continue 
to live either independently or with their families.
The model that I have outlined is not a pipe dream. It 
is an affordable prescription for a commitment to ensure 
that people with schizophrenia receive the basic minimum 
package of evidence-based care in LAMIC, care that meets 
their human rights.
Saeed Farooq’s Viewpoint: Directly Observed 
Therapy (DOTS) Is an Approach Worth Testing
In developing countries, treatment for schizophrenia 
is limited mostly to acute episodes and seldom involves 
primary care physicians. Developing countries typically 
spend less than 1% of their health budget on mental health 
[15], and one of the consequences of this under-spending 
is a high prevalence of untreated schizophrenia in the form 
of undetected as well as inadequately and partially treated 
cases. In Bihar, one poor state in India, there are more 
people suffering from schizophrenia than in the whole of 
North America [16]. The high prevalence in developing 
countries is partly explained by the predominantly younger 
population of the developing world (schizophrenia is a 
disease of young adults).
One approach to tackling the burden of untreated 
schizophrenia in low-income countries that may prove 
effective is directly observed therapy. This approach is the 
cornerstone of current global efforts to tackle tuberculosis 
(TB). Successful TB treatment, and the prevention of multi-
drug resistant TB, requires long-term therapy and high 
adherence rates. The internationally recommended TB 
strategy known as DOTS (Directly Observed Therapy, Short-
Course) [17] has two essential components: (1) a regular 
uninterrupted supply of a standardized treatment regimen of 
six to eight months chemotherapy, and (2) its administration 
under the supervision of a health worker or trained close 
relative who watches and records the patient swallowing the 
correct dose of drugs. A discussion of all ﬁ  ve components of 
DOTS and its implementation is found in [17].
The DOTS strategy has led to remarkable improvements 
in TB control in many developing countries [18,19]. The 
World Bank considers DOTS to be one of the most cost-
effective health interventions, more cost-effective than 
self-administered treatment [20,21]. I would argue that the 
principles underlying the DOTS strategy could form the basis 
for an effective public health intervention to cope with the 
burden of schizophrenia in developing countries.
Providing a regular supply of antipsychotic medication 
and supervising its administration may be one mechanism 
for addressing the enormous public health burden of long-
term untreated psychosis in developing countries. This 
burden includes increased co-morbid substance abuse, 
suicide, treatment resistance, impaired cognitive and 
neuropsychological function, offending behavior, vocational 
failure, and overall poor outcome [22]. In addition, 
the strongest predictor of relapse is discontinuation of 
medication, which increases the relapse risk 5-fold [23]. 
Even a very short break from taking medication (just one to 
ten days over a one-year period) is signiﬁ  cantly associated 
with increased risk of hospitalization (odds ratio 1.98, 95%, 
conﬁ  dence interval 1.27–3.25) [24].
Long-term antipsychotic medication for treating 
schizophrenia in developing countries is a cost-effective 
intervention. Out of 20 recommendations for optimal 
treatment suggested by the Schizophrenia Patient Outcome 
Research Team, a research team funded by the US National 
Institute of Mental Health, 14 were related to pharmacological 
interventions [25]. These interventions were also rated 
highest on ease of implementation and can be implemented 
in developing countries, provided access to the drugs is 
ensured through a programme akin to DOTS. The cost of 
antipsychotic medication, including recent atypical drugs, is 
surprisingly very low in many developing countries [16].
We surely owe it to the families of patients with 
schizophrenia in poor countries to provide free drugs. The 
families have largely subsidized schizophrenia treatment 
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for society and the state at large by providing the social, 
psychological, residential, and occupational support that 
constitutes the major proportion of the cost of treatment 
for this disorder. Provision of free drugs to these patients as 
a part of “DOTS-type” programme would help to share this 
burden in a small but very signiﬁ  cant way.
Drug treatment for schizophrenia is likely to be more 
effective if its administration is supervised. Such a system of 
supervision is feasible in low-income settings in view of the 
family’s integral involvement in the patient’s care. About 
60% of patients with schizophrenia may fail to adhere to their 
treatment [26], in part because the disease itself leads to 
impaired insight and cognitive functioning. Approaches that 
are broadly similar to DOTS, entrusting the monitoring of 
drug compliance to a relative, have been found to be effective 
in improving treatment adherence for schizophrenia in 
developing countries [27,28,11].
I suggest that patients with schizophrenia in the developing 
world be supplied free access to drugs for two years under 
close supervision. This will help to overcome non-adherence 
during the period of the illness (i.e., the ﬁ  rst two years) that 
has been shown to be the strongest predictor of long-term 
outcome and disability [29]. Indeed, a recent systematic 
review of interventions to address non-adherence in 
people with schizophrenia also recommended that clinical 
interventions targeting non-adherence should continue for 
at least 18 months [30]. In our pilot project, we found that 
a supervised treatment approach was associated with greater 
adherence rates. Encouraged by this ﬁ  nding, we have started 
a randomized controlled trial of “Supervised Treatment 
of Outpatient Schizophrenia (STOPS)” to evaluate its 
effectiveness versus usual care (further details available from 
author on request and at http://www.clinicaltrials.gov/ct/
show/NCT00392249?order=1).
Would direct observation of schizophrenia treatment be 
overly coercive? In view of the wide treatment gap, there will 
always be a large population of those with schizophrenia who 
will be willing to take treatment under supervision, and they 
must be provided with effective interventions. Moreover, in 
view of the present poor state of mental health legislation 
in many developing countries, patients with untreated 
schizophrenia are likely to suffer from much greater human 
rights abuses than those who are treated.
Effective treatments for schizophrenia have neither 
been applied optimally nor advocated as public health 
interventions in developing countries. A public health 
intervention for schizophrenia modeled on DOTS may lead 
to greater awareness of the beneﬁ  ts of treatment and may 
encourage untreated patients to seek help earlier in the 
course of their illness. Promoting awareness of the beneﬁ  ts of 
treatments may help to reduce the stigma of schizophrenia, 
just as the advent and effective implementation of anti-
tuberculosis treatment did for TB. A community intervention 
for schizophrenia based on the principles of DOTS could 
also help to put mental health strongly on the public health 
agenda.
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R. Thara’s Viewpoint: We Must Tackle Stigma 
by Offering Proven Treatments
The incidence and prevalence of schizophrenia does 
not vary widely enough across the world to merit markedly 
different local treatment approaches or programmes [1,31]. 
However, the reality is that there are widespread differences 
in the treatment that people with schizophrenia receive in 
different parts of the world. Understanding the reasons for 
these differences is the key to improving the care of people 
with schizophrenia in developing countries, including India, 
where I work.
An important reason underscoring these differences is that 
many developing countries have far too few mental health 
professionals [3], reﬂ  ecting the very low priority accorded 
to mental health by many governments. In many low-income 
countries, there is an urgent need to improve and expand 
mental health services.
Community care in India is almost synonymous with family 
care. There are no organized community-based programmes 
for people with chronic mental illness. The commonest 
site of treatment is the mental hospital, many of which are 
large and isolated, with little contact with the community 
they serve. Efforts are under way to improve the conditions 
of many of these hospitals. While the number of general 
hospital psychiatry beds has increased in the last decade, 
the total number is still grossly inadequate. Most private 
psychiatrists are located in urban areas. There are very few 
non-governmental organizations, and these are largely 
concentrated in the southern part of the country.
India’s National Mental Health Programme did envisage 
the diffusion of mental health skills to primary health-care 
centres at the village and district levels, and the integration of 
mental health with primary care. However, poor monitoring 
and lack of coordination with the local state governments 
meant that such diffusion and integration efforts were 
not implemented, with the exception of a few sporadic 
programmes.
In India, people with chronic mental illness do not 
generally receive any welfare beneﬁ  ts, except for some minor 
beneﬁ  ts in just a few areas. Medical insurance seldom covers 
treatment of mental disorders. The result is that families have 
to bear the entire costs of the treatment and ongoing care 
of these patients. A heavy ﬁ  nancial, physical, and emotional 
burden is therefore imposed upon family members. Indeed, 
over 90% of patients with schizophrenia live at home with 
their families [32]. Such family involvement is not merely 
a result of close kinship ties, but is also due to inadequate 
treatment facilities. Religious and traditional modes of 
intervention are still widely practiced, especially in rural 
areas, where mental health services are almost non-existent. 
Families are equal partners in all stages of intervention, be it 
choice of a drug, detection of side effects, or early symptoms 
of relapse, ensuring compliance with medication and 
supporting the affected family member through life events 
such as jobs or marriages.
Stigma, and the presence of competing and conﬂ  icting 
explanatory models of mental illness (often based on 
“magico-religious” beliefs), have also contributed to the non-
use of existing treatment facilities. A study that we conducted 
at the Schizophrenia Research Foundation in Chennai found 
that women with schizophrenia were more stigmatized than 
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men with schizophrenia, and that female caregivers were 
more sensitive to stigma than male caregivers. Being single 
or divorced compounded the problem of stigma even further 
[33]. Stigma is an all-encompassing phenomenon and a 
profound barrier to effective help seeking.
In terms of the availability of medication for treating 
schizophrenia in India, both ﬁ  rst and second generation 
antipsychotics (risperidone, olanzapine, clozapine, quetiepine, 
and sulpiride) are available at fairly low prices. Both groups 
of drugs are being used as ﬁ  rst-line medication. In my clinical 
experience I have found that Indian patients require a much 
lower dosage of medicines than patients in the West, in both 
the acute and maintenance phases of treatment. However, 
more research is needed to document whether there are 
indeed different dosage requirements in Indian patients and, 
if there are, to critically address the actual reasons for this 
difference. Unfortunately, a large proportion of patients in 
both rural and urban settings remain untreated [34,35]. Even 
when patients are prescribed medication, non-compliance 
during the symptomatic phase is common in India. In our 
study of patients attending an urban outpatient care center, 
we noted that when the patients were acutely ill and refused 
to take medication, in half the cases the families administered 
medication to them without the patients’ knowledge, under 
the supervision of the psychiatrist [32].
Given all of these different factors affecting the current 
management of schizophrenia, what can be done to improve 
such care? Ensuring that patients receive effective treatments 
promises to be the best antidote to stigma. When patients’ 
conditions improve, especially in the restoration of their 
social functioning, the community’s explanatory model 
of schizophrenia often shifts from a magico-religious to 
a medico-social viewpoint. The National Mental Health 
Programme will have to be scaled up to ensure that 
mental health care reaches the masses. At the same time, 
the government should plan and implement awareness 
programmes for schizophrenia all over the country, as it did 
for leprosy and tuberculosis.
Efforts will simultaneously have to be made to prevent Indian 
psychiatrists from going abroad, since their numbers have 
dwindled rapidly in the last few years. More psychiatry tuition 
in the undergraduate medical curriculum is also critical. 
Unless all these measures are implemented urgently and in a 
comprehensive manner, mental health care will continue to 
languish in the backyards of the health-care system.  
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